胃肠道表观遗传改变作为癌症生物标志物的当前与新兴应用
本文综述了结直肠癌、肝癌、胃癌、胰腺癌和食管癌中表观遗传改变作为生物标志物的应用。表观遗传改变已成为最稳健的生物标志物类别之一,用于癌症风险判断、早期检测、预后判断和治疗反应预测,并是越来越多临床筛查和监测检测的基础。
要点
- 表观遗传改变是胃肠道癌症最稳健的生物标志物类别之一。
- 可用于癌症风险判断、早期检测、预后判断和治疗反应预测。
- 表观遗传标志物是越来越多临床筛查和监测检测的基础。
核心结论
- 表观遗传改变已成为胃肠道癌症最稳健的生物标志物类别之一,并是越来越多临床筛查和监测检测的基础。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 结直肠癌、肝癌、胃癌、胰腺癌和食管癌是全球癌症相关死亡的主要原因。
- 几乎所有胃肠道癌症的基本特征是基因组和表观基因组DNA改变。
- 这些改变以及其他宿主和微环境因素最终介导癌前病变和癌症的临床行为,并可用作生物标志物。
临床怎么用
- 表观遗传改变可用于癌症风险判断、早期检测、预后判断和治疗反应预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer, liver cancer, stomach cancer, pancreatic cancer, and esophageal cancer are leading causes of cancer-related deaths worldwide. A fundamental trait of virtually all gastrointestinal cancers is genomic and epigenomic DNA alterations. Cancer cells acquire genetic and epigenetic alterations that drive the initiation and progression of the cancers by altering the molecular and cell biological processes of the cells. These alterations, as well as other host and microenvironment factors, ultimately mediate the clinical behavior of the precancers and cancers and can be used as biomarkers for cancer risk determination, early detection of cancer and precancer, determination of the prognosis of cancer and prediction of the response to therapy. Epigenetic alterations have emerged as one of most robust classes of biomarkers and are the basis for a growing number of clinical tests for cancer screening and surveillance.
引用
- Grady WM, Yu M, Markowitz SD, et al. Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Gastroenterology. 2020. PMID: 33279516. doi:10.1053/j.gastro.2020.09.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。